Stockreport

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Nkarta, Inc.  (NKTX) 
PDF Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, [Read more]